Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695878 | 0.93 | SIGMAR1 (0.58) | SIGMAR1EPHX2CCR3 | |
| SCHEMBL6708092 | 0.92 | KMT2A (0.47) | KMT2AMEN1SIGMAR1ALOX5EPHX2 | |
| SCHEMBL6702012 | 0.91 | DRD4 (0.52) | SIGMAR1LMNA | |
| SCHEMBL6703098 | 0.91 | KMT2A (0.50) | KMT2AMEN1SIGMAR1CCR3 | |
| SCHEMBL6700051 | 0.89 | DRD4 (0.54) | KMT2AMEN1SIGMAR1CCR3 | |
| SCHEMBL6701288 | 0.89 | RAB9A (0.55) | SIGMAR1EPHX2CCR3 | |
| SCHEMBL6989123 | 0.89 | KMT2A (0.56) | KMT2AMEN1SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL6699771 | 0.88 | SIGMAR1 (0.46) | KMT2AMEN1SIGMAR1CCR3 | |
| SCHEMBL6698789 | 0.88 | ACHE (0.51) | KMT2AMEN1SIGMAR1ALOX5 | |
| SCHEMBL6702902 | 0.88 | MAPT (0.57) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HONG YUFENG (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1332127-A2 | AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS | Warner-Lambert Company LLC (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002036554-A2 | AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HTR7, HTR1A, HTR2C | KMT2A 4351/4885MEN1 3611/4885SIGMAR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.